Cargando…

Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis

SUMMARY: We explored relations between serum hepatocyte growth factor (HGF), disease activity, osteoproliferation, and bone mineral density (BMD) in ankylosing spondylitis (AS), in comparison with healthy controls. HGF was increased especially in male AS patients and smokers and associated with both...

Descripción completa

Detalles Bibliográficos
Autores principales: Torres, L., Klingberg, E., Nurkkala, M., Carlsten, H., Forsblad-d’Elia, H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer London 2018
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449322/
https://www.ncbi.nlm.nih.gov/pubmed/30306221
http://dx.doi.org/10.1007/s00198-018-4721-4
_version_ 1783408819008700416
author Torres, L.
Klingberg, E.
Nurkkala, M.
Carlsten, H.
Forsblad-d’Elia, H.
author_facet Torres, L.
Klingberg, E.
Nurkkala, M.
Carlsten, H.
Forsblad-d’Elia, H.
author_sort Torres, L.
collection PubMed
description SUMMARY: We explored relations between serum hepatocyte growth factor (HGF), disease activity, osteoproliferation, and bone mineral density (BMD) in ankylosing spondylitis (AS), in comparison with healthy controls. HGF was increased especially in male AS patients and smokers and associated with both lower BMD and more chronic radiographic changes in the spine. INTRODUCTION: Ankylosing spondylitis (AS) is characterized by both osteoproliferation and increased bone loss. Biomarkers are requested to predict the processes. The aims of this study were to compare serum levels of hepatocyte growth factor (HGF), matrix metalloproteinase-3 (MMP-3), and vascular endothelial growth factor (VEGF) in AS patients with healthy controls (HC) and to explore the associations with disease activity, osteoproliferation, and bone mineral density (BMD). METHODS: Serum from AS patients (modified NY-criteria) and HC was analyzed for HGF, MMP-3, and VEGF with ELISA. Disease activity parameters were collected. Osteoproliferation was assessed with modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and BMD was measured in femoral neck. RESULTS: Totally, 204 AS patients and 80 sex and age matched HC were included. Serum HGF was higher in the AS patients compared with the HC, whereas serum MMP-3 and VEGF were not. Serum HGF was also higher in smokers and in the male AS patients positively correlated with age, BASMI, and mSASSS, and negatively correlated with BMD. The biomarkers were all positively associated with ESR, CRP, and WBC. In multiple linear regression analysis serum HGF remained associated with higher mSASSS and lower BMD, after adjusting for age, sex, CRP, smoking, and body mass index. CONCLUSIONS: Serum HGF was increased in male AS patients and associated with higher mSASSS and lower BMD. In addition, serum HGF was positively associated with risk factors for osteoproliferation such as age, CRP and smoking. HGF could be a potential biomarker of importance for the bone metabolism in AS. TRIAL REGISTRATION: NCT00858819.
format Online
Article
Text
id pubmed-6449322
institution National Center for Biotechnology Information
language English
publishDate 2018
publisher Springer London
record_format MEDLINE/PubMed
spelling pubmed-64493222019-04-17 Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis Torres, L. Klingberg, E. Nurkkala, M. Carlsten, H. Forsblad-d’Elia, H. Osteoporos Int Original Article SUMMARY: We explored relations between serum hepatocyte growth factor (HGF), disease activity, osteoproliferation, and bone mineral density (BMD) in ankylosing spondylitis (AS), in comparison with healthy controls. HGF was increased especially in male AS patients and smokers and associated with both lower BMD and more chronic radiographic changes in the spine. INTRODUCTION: Ankylosing spondylitis (AS) is characterized by both osteoproliferation and increased bone loss. Biomarkers are requested to predict the processes. The aims of this study were to compare serum levels of hepatocyte growth factor (HGF), matrix metalloproteinase-3 (MMP-3), and vascular endothelial growth factor (VEGF) in AS patients with healthy controls (HC) and to explore the associations with disease activity, osteoproliferation, and bone mineral density (BMD). METHODS: Serum from AS patients (modified NY-criteria) and HC was analyzed for HGF, MMP-3, and VEGF with ELISA. Disease activity parameters were collected. Osteoproliferation was assessed with modified Stoke Ankylosing Spondylitis Spine Score (mSASSS) and BMD was measured in femoral neck. RESULTS: Totally, 204 AS patients and 80 sex and age matched HC were included. Serum HGF was higher in the AS patients compared with the HC, whereas serum MMP-3 and VEGF were not. Serum HGF was also higher in smokers and in the male AS patients positively correlated with age, BASMI, and mSASSS, and negatively correlated with BMD. The biomarkers were all positively associated with ESR, CRP, and WBC. In multiple linear regression analysis serum HGF remained associated with higher mSASSS and lower BMD, after adjusting for age, sex, CRP, smoking, and body mass index. CONCLUSIONS: Serum HGF was increased in male AS patients and associated with higher mSASSS and lower BMD. In addition, serum HGF was positively associated with risk factors for osteoproliferation such as age, CRP and smoking. HGF could be a potential biomarker of importance for the bone metabolism in AS. TRIAL REGISTRATION: NCT00858819. Springer London 2018-10-10 2019 /pmc/articles/PMC6449322/ /pubmed/30306221 http://dx.doi.org/10.1007/s00198-018-4721-4 Text en © The Author(s) 2018 Open Access This article is distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/), which permits any noncommercial use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.
spellingShingle Original Article
Torres, L.
Klingberg, E.
Nurkkala, M.
Carlsten, H.
Forsblad-d’Elia, H.
Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis
title Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis
title_full Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis
title_fullStr Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis
title_full_unstemmed Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis
title_short Hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis
title_sort hepatocyte growth factor is a potential biomarker for osteoproliferation and osteoporosis in ankylosing spondylitis
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6449322/
https://www.ncbi.nlm.nih.gov/pubmed/30306221
http://dx.doi.org/10.1007/s00198-018-4721-4
work_keys_str_mv AT torresl hepatocytegrowthfactorisapotentialbiomarkerforosteoproliferationandosteoporosisinankylosingspondylitis
AT klingberge hepatocytegrowthfactorisapotentialbiomarkerforosteoproliferationandosteoporosisinankylosingspondylitis
AT nurkkalam hepatocytegrowthfactorisapotentialbiomarkerforosteoproliferationandosteoporosisinankylosingspondylitis
AT carlstenh hepatocytegrowthfactorisapotentialbiomarkerforosteoproliferationandosteoporosisinankylosingspondylitis
AT forsbladdeliah hepatocytegrowthfactorisapotentialbiomarkerforosteoproliferationandosteoporosisinankylosingspondylitis